A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

NCT07223138 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

1560

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Psoriatic

Interventions

DRUG: Sonelokimab

Sponsor

MoonLake Immunotherapeutics AG